Use of a swertia japonica extract in whitening and / or yellowing

Abstract

The application discloses application of an extract of swertia mileensis in whitening and / or yellow-removing, and belongs to the technical field of daily chemical products. The application first proposes the application of the extract of swertia mileensis in whitening and / or yellow-removing. For example, the extract of swertia mileensis can effectively inhibit melanin production of B16-F10 cells and improve ITA of human skin, so that the whitening effect is realized. In addition, the extract of swertia mileensis can promote expression of UGT1A1, a gene related to bilirubin metabolism of HaCaT cells, and play a yellow-removing effect by promoting bilirubin metabolism. Moreover, the extract of swertia mileensis can also reduce bilirubin content of skin, reduce redness a* value and yellowness b* value of skin, and improve brightness L* value of skin, thereby playing a yellow-removing effect. In other words, the extract of swertia mileensis can effectively solve problems such as skin pigmentation, dullness and yellowing, and has a great application prospect in preparation of daily chemical products and / or medicines with the whitening and / or yellow-removing effect.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of daily chemical products, in particular to an application of a swertia mileensis extract in whitening and / or yellowing removal. BACKGROUND

[0002] With the development of economy and the improvement of living standards, consumers' demand for skin beauty is increasing, especially in the aspects of whitening and yellowing removal. Whitening is not only to pursue brighter skin color, but also an important manifestation of modern people's pursuit of health and young appearance. Yellowing removal is aimed at the problem of skin darkening and yellowing caused by internal and external factors, helping consumers achieve more uniform and energetic skin color. Therefore, active ingredients with dual effects of whitening and yellowing removal are favored in the skin care market and become a research hotspot.

[0003] Current common whitening active ingredients include hydroquinone, vitamin C, kojic acid and arbutin, which mainly play a role through mechanisms such as inhibition of tyrosinase activity, antioxidant and blocking of melanin transmission. However, these traditional whitening ingredients have limitations: for example, although hydroquinone has a significant whitening effect, long-term use can cause skin irritation, allergy and even pigment abnormalities; vitamin C has poor stability and is easily oxidized; kojic acid and arbutin may cause sensitivity when used at high concentrations. In addition, although the market demand for whitening is booming, there are relatively few effective solutions to the problem of skin yellowing.

[0004] In view of this, the present application is proposed. SUMMARY

[0005] The purpose of the present application is to provide an application of a swertia mileensis extract in whitening and / or yellowing removal, so as to solve or improve the above technical problems.

[0006] The present application can be achieved as follows:

[0007] In a first aspect, the present application provides an application of a swertia mileensis extract in whitening and / or yellowing removal.

[0008] In an optional embodiment, the swertia mileensis extract is used for inhibiting melanin production.

[0009] In an optional embodiment, the swertia mileensis extract is used for increasing the expression of UGT1A1 gene.

[0010] In an optional embodiment, the swertia mileensis extract is used for reducing the content of bilirubin in the skin.

[0011] In an optional embodiment, the swertia mileensis extract is used for reducing the yellowness b* value of the skin.

[0012] In an optional embodiment, the swertia mileensis extract is used for reducing the redness a* value of the skin.

[0013] In an alternative embodiment, the extract of Swertia mileensis is used to increase the skin brightness L* value.

[0014] In an alternative embodiment, the extract of Swertia mileensis is used to increase the skin ITA° value.

[0015] In an alternative embodiment, the effective concentration of the extract of Swertia mileensis is 0.01wt% to 5wt%.

[0016] In an alternative embodiment, the effective concentration of the extract of Swertia mileensis is 0.01wt% to 0.2wt%.

[0017] In an alternative embodiment, the preparation of the extract of Swertia mileensis comprises: extracting the crushed Swertia mileensis leaves with an organic solvent; wherein the organic solvent is an ethanol-water solution with an ethanol concentration of 65% to 75%, the ratio of the amount of the organic solvent to the amount of the Swertia mileensis leaves is 8mL:1g to 12mL:1g, the extraction temperature is 48°C to 52°C, and the extraction time is 46h to 50h.

[0018] In a second aspect, the present application provides a daily-use product containing the extract of Swertia mileensis.

[0019] In an alternative embodiment, the daily-use product comprises a cosmetic product.

[0020] In an alternative embodiment, the cosmetic product comprises a skin care lotion, a skin care milk, a skin care cream, a facial cleanser, or a hair care lotion.

[0021] In an alternative embodiment, the dosage form of the daily-use product comprises a solution, a suspension, an emulsion, a cream, a gel, an ointment, a paste, a spray, or a patch.

[0022] In a third aspect, the present application provides a medicine containing the extract of Swertia mileensis.

[0023] The beneficial effects of the present application include:

[0024] The application first proposes the application of the extract of swertia mileensis in whitening and / or yellowing removal, for example, the extract of swertia mileensis can effectively inhibit the melanin production of B16-F10 cells and improve the ITA° value of human skin, thereby realizing the whitening effect; in addition, the extract of swertia mileensis can promote the expression of UGT1A1 gene related to bilirubin metabolism of HaCaT cells, thereby playing a role in yellowing removal through promoting bilirubin metabolism. In addition, the extract of swertia mileensis can also reduce the content of skin bilirubin, reduce the redness a* value and yellowness b* value of the skin, and improve the brightness L* value of the skin, thereby playing a role in yellowing removal. In other words, the extract of swertia mileensis has both whitening and yellowing removal effects, can effectively solve the problems of skin pigmentation, dullness and yellowing, can meet the needs of consumers for uniform and bright skin color, can effectively deal with the problems of dullness and yellowing, and can improve the overall competitiveness of related daily chemical products and / or drugs, thereby having a broad market prospect and commercial value. BRIEF DESCRIPTION OF DRAWINGS

[0025] In order to more clearly illustrate the technical solutions of the embodiments of the application, the drawings needed in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the application, and therefore should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can also be obtained without creative labor on the basis of these drawings.

[0026] Figure 1 The result graph of the cytotoxicity experiment in Example 2;

[0027] Figure 2 The result graph of the melanin inhibition experiment in Example 3;

[0028] Figure 3 The result graph of the determination of the expression level of bilirubin metabolism related gene UGT1A1 gene in Example 4;

[0029] Figure 4 The result graph of the content of skin bilirubin in Example 5;

[0030] Figure 5 The result graph of the brightness L* value of the skin in Example 5;

[0031] Figure 6 The result graph of the redness a* value of the skin in Example 5;

[0032] Figure 7 The result graph of the yellowness b* value of the skin in Example 5;

[0033] Figure 8 The result graph of the ITA° value of the skin in Example 5. DETAILED DESCRIPTION

[0034] In order to make the purposes, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. The specific conditions not mentioned in the embodiments are carried out according to the conventional conditions or the conditions suggested by the manufacturers. The reagents or instruments not mentioned by the manufacturers are all conventional products that can be purchased in the market.

[0035] The application of the extract of swertia mileensis in whitening and / or yellow-removing will be specifically described below.

[0036] At present, the extract of swertia mileensis is mainly used for clearing heat and detoxifying, promoting diuresis and detumescence, inhibiting bacteria or tightening skin. The present application creatively provides a new use of the extract of swertia mileensis, specifically, the extract of swertia mileensis is used for whitening and / or yellow-removing.

[0037] In some embodiments, the extract of swertia mileensis is used for whitening; in other embodiments, the extract of swertia mileensis is used for yellow-removing; in other embodiments, the extract of swertia mileensis is used for both whitening and yellow-removing.

[0038] In the present application, the extract of swertia mileensis can be used for inhibiting melanin production, thereby playing a whitening effect by inhibiting the production of melanin.

[0039] In the present application, the extract of swertia mileensis can also be used for improving the expression of UGT1A1 gene. As a gene related to bilirubin metabolism of HaCaT cells, the extract of swertia mileensis can improve the expression of UGT1A1 gene, thereby playing an effect of promoting bilirubin metabolism, and further reducing the content of bilirubin in the skin, and playing a yellow-removing effect.

[0040] In some embodiments, the extract of swertia mileensis can be used for reducing the redness a* value of the skin; in some embodiments, the extract of swertia mileensis can be used for reducing the yellowness b* value of the skin; in some embodiments, the extract of swertia mileensis can be used for improving the brightness L* value of the skin; in some embodiments, the extract of swertia mileensis can be used for improving the ITA° value of the skin. Wherein, ITA° (Individual Typological Angle, ITA°) refers to an individual type angle, which is an index commonly used in skin color grading. The ITA angle is the position angle of the skin color of the measured individual in the geometric plane composed of L* and b* values. The grade of the skin color is determined according to the angle. The larger the ITA angle, the lighter the skin color, and the smaller the ITA angle, the darker the skin color.

[0041] In some embodiments, the effective concentration of the extract of Swertia mileensis can be 0.01wt% to 5wt%, such as 0.01wt%, 0.02wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.5wt%, 1wt%, 2wt%, 3wt%, 4wt% or 5wt%, or other values within the range of 0.01wt% to 5wt%. In some typical embodiments, the effective concentration of the extract of Swertia mileensis is 0.01wt% to 0.2wt%.

[0042] Within the above range of effective concentration, the extract of Swertia mileensis can achieve better whitening and yellow-removing effects while ensuring safety.

[0043] In some alternative embodiments, the preparation of the extract of Swertia mileensis can include: extracting the crushed Swertia mileensis leaves with an organic solvent; wherein the organic solvent is an ethanol-water solution with an ethanol concentration of 65wt% to 75wt%, the ratio of the organic solvent to the Swertia mileensis leaves is 8mL:1g to 12mL:1g, the extraction temperature is 48°C to 52°C, and the extraction time is 46h to 50h.

[0044] In some typical embodiments, the preparation of the extract of Swertia mileensis can be carried out as follows:

[0045] S1: Collect fresh or dried leaves from healthy mature Swertia mileensis plants. If dried leaves are used, ensure that they are completely dried and free of mold.

[0046] S2: Crush the collected Swertia mileensis leaves into fine powder to increase the surface area in contact with the solvent, thereby improving the extraction efficiency. Avoid excessive heating during the crushing process to protect the active ingredients in the leaves.

[0047] S3: Use an ethanol-water solution with an ethanol concentration of 70wt% as the solvent, the ratio of the solvent to the Swertia mileensis leaves is 10mL:1g, and the extraction is carried out at 50°C for 48h. This temperature condition can effectively extract the active ingredients in Swertia mileensis while avoiding the loss of heat-sensitive components. Use mechanical stirring to keep the mixture uniform and improve the extraction efficiency.

[0048] S4: Use a cloth bag filter to preliminarily filter the extracted solution to remove large particles of solids, and then continue to use a precision filter membrane to finely filter the filtrate after preliminary filtration to ensure the purity of the extract.

[0049] S5: Use a rotary evaporator to concentrate the filtrate obtained after fine filtration at 35°C, keeping the evaporation temperature low to prevent decomposition of active ingredients.

[0050] It should be noted that the extract of swertia mileensis in the present application can also be a commercially available product (i.e. directly purchased) or can be prepared by referring to the prior art. Under the same action concentration, the extract of swertia mileensis prepared by the method provided in the present application can achieve better whitening and yellow-removing effects.

[0051] In summary, the present application first proposes the application of the extract of swertia mileensis in whitening and / or yellow-removing. For example, the extract of swertia mileensis can effectively inhibit the melanin production of B16-F10 cells and increase the ITA° value of human skin, thereby achieving the whitening effect. In addition, the extract of swertia mileensis can promote the expression of UGT1A1 gene related to bilirubin metabolism of HaCaT cells, thereby playing a role in yellow-removing by promoting bilirubin metabolism. Moreover, the extract of swertia mileensis can also reduce the content of bilirubin in the skin, reduce the b* value of the skin and increase the L* value of the skin, thereby playing a role in yellow-removing. In other words, the extract of swertia mileensis has both whitening and yellow-removing effects, which can effectively solve the problems of skin pigmentation, dullness and yellowing, can meet the needs of consumers for uniform and bright skin color, can effectively deal with the problems of dullness and yellowing, can improve the overall competitiveness of related daily chemical products and / or drugs, and has broad market prospects and commercial value.

[0052] In addition, the present application also provides a daily chemical product containing the extract of swertia mileensis.

[0053] In some optional embodiments, the daily chemical product includes a cosmetic product, which exemplarily but non-limitingly includes skin care water, skin care milk, skin care cream, facial cleanser or hair care water, etc. The dosage form of the daily chemical product exemplarily but non-limitingly includes solution, suspension, emulsion, cream, gel, ointment, paste, spray or patch, etc.

[0054] In addition, the present application also provides a drug containing the extract of swertia mileensis.

[0055] The daily chemical product and the drug containing the extract of swertia mileensis both have certain whitening and yellow-removing effects.

[0056] The features and performances of the present application are further described in detail below in combination with embodiments.

[0057] Embodiment 1

[0058] The present embodiment provides an extract of swertia mileensis, and the preparation method thereof is as follows:

[0059] S1: Collect fresh or dried leaves from healthy mature swertia mileensis plants.

[0060] S2: Crush the collected swertia mileensis leaves into fine powder.

[0061] S3: Ethanol-water solution with ethanol concentration of 70wt% was used as solvent, the ratio of solvent to leaf of Swertia mileensis Hsiao was 10mL:1g, and the extraction was carried out at 50℃ for 48h.

[0062] S4: The obtained extract was preliminarily filtered using a cloth bag filter to remove large particles, and then the filtrate was further filtered using a precision filter membrane.

[0063] S5: The obtained filtrate was concentrated using a rotary evaporator at 35℃ until the solid content was 40wt%.

[0064] Example 2

[0065] Cytotoxicity experiment

[0066] (1) Cell plating

[0067] First, after the B16-F10 cells (mouse melanoma cells) were fully grown in the culture dish, the old culture medium was discarded and washed once with 0.01mol / L PBS buffer with pH of 7.2, and then the PBS was discarded. Next, 1mL trypsin was added to the culture dish, which was placed in a cell incubator (37℃, 5% CO2) for about 1.5min for digestion. After the digestion was completed, 3mL DMEM complete medium was added to terminate the digestion reaction, and the cells were transferred to a 15mL centrifuge tube using a pipette at a speed of 1000rpm for 5min. After centrifugation, the supernatant was discarded, 1mL fresh culture medium was added, and the cells were gently suspended using a pipette. The density of the cells in the suspension was quantified using a cell counter, and after the cell density was determined, the cell suspension was adjusted to a density of 5x10 4 6 / mL, and inoculated into a 96-well plate at a seeding volume of 100μL / well. Finally, the 96-well plate was placed back into a 37℃ cell incubator for 24 hours.

[0068] (2) Drug administration

[0069] The Swertia mileensis extract was diluted with PBS buffer to the desired concentration. For the sample group, 10μL of the Swertia mileensis extract at different concentrations was added to each well, and 6 replicate wells were set for each concentration. At this time, the final concentration of the Swertia mileensis extract was 8%, 5%, 4%, 2%, 1%, 0.5%, 0.25% and 0.125%. For the control group, 10μL of PBS buffer was added, and 6 replicate wells were also set. After completion, the 96-well plate was placed into a 37℃ cell incubator for 24 hours.

[0070] (3) Cell viability detection

[0071] First, CCK-8 reagent and DMEM culture medium were mixed at a volume ratio of 1:10 to obtain the working solution. Then, the old culture medium in the 96-well plate was gently aspirated using a pipette to avoid damaging the cells. 100 μL of the working solution was added to each well. After addition, the plate was carefully placed in a cell culture incubator at 37°C and incubated for approximately 1 hour to allow the CCK-8 to fully react with the cells and produce a detectable color change. After incubation, the 96-well plate was removed and immediately subjected to dual-wavelength assay using a microplate reader. The dominant wavelength was set to 450 nm and the reference wavelength to 630 nm. This dual-wavelength assay method can accurately assess the viability and proliferation status of cells within the wells.

[0072] (4) Data Analysis

[0073] After the test, the obtained data were analyzed. The formula for calculating cell viability is as follows:

[0074] Where As represents the absorbance of the sample group and Ac represents the average absorbance of the control group.

[0075] The independent samples t-test was used to analyze the significant differences between the sample treatment group and the control group. P < 0.05 was considered statistically significant, *P < 0.05, **P < 0.01.

[0076] (5) Experimental Results

[0077] Cytotoxicity test results as follows Figure 1 As shown, by Figure 1 It can be seen that, within the concentration range of 0.125% to 8%, the extract of *Gynostemma pentaphyllum* has no cytotoxic effect on B16 cells.

[0078] Example 3

[0079] Melanin inhibition experiment

[0080] (1) Cell plating

[0081] B16-F10 cells were loaded at 15 × 10 4 The cells were seeded at a density of 10 cells / mL into 100mm cell culture dishes, with a seeding volume of 10mL / dish. After seeding, the culture dishes were placed in a 37℃ cell culture incubator for 24 hours.

[0082] (2) Administration

[0083] The culture dishes were divided into nine groups: blank control group, positive control group, 0.01% gentian root group, 0.05% gentian root group, 0.1% gentian root group, 0.2% gentian root group, 0.5% gentian root group, 1% gentian root group, and 5% gentian root group, with three replicates for each group. Phenethyl resorcinol (abbreviated as "377") was used as a positive control, with a final concentration of 2 ppm. After administration, the cells were incubated at 37°C for 24 h.

[0084] (3) Melanin content detection

[0085] Cells were digested with trypsin and collected by centrifugation. After discarding the supernatant, the cells were washed twice with PBS, and the supernatant was discarded again. 300 μL of 1 mol / L NaOH containing 10% DMSO was added, and the cells were placed in an 80°C water bath for 30 min to lyse them. After lysis, 200 μL of cell lysis buffer was transferred to a 96-well plate, and the absorbance at 405 nm was read using a microplate reader. The absorbance was then converted into melanin content, with the control group having a melanin content of 100%.

[0086] (4) Data Analysis

[0087] After the test, the obtained data were analyzed. The formula for calculating the melanin inhibition rate is as follows:

[0088] Where As represents the absorbance of the sample group and Ac represents the average absorbance of the blank control group.

[0089] The independent samples t-test was used to analyze the significant differences between the sample treatment group and the control group. P < 0.05 was considered statistically significant, *P < 0.05, **P < 0.01.

[0090] (5) Experimental Results

[0091] The results of the melanin inhibition experiment are as follows: Figure 2 As shown, by Figure 2 It can be seen that within the concentration range of 0.01% to 5%, the inhibitory ability of *Gentiana scabra* extract on melanin in B16-F10 cells gradually increased with increasing concentration. At concentrations of 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, and 5%, the melanin inhibition rates on B16-F10 cells were 3.9%, 6.7%, 9.6%, 11.7%, 12.0%, 14.0%, and 17.8%, respectively, indicating that *Gentiana scabra* extract has good whitening effects.

[0092] Example 4

[0093] Measurement of expression level of UGT1A1 gene, a gene related to bilirubin metabolism

[0094] (1) Cell inoculation

[0095] HaCaT cells (human immortalized keratinocytes) grown in 1640 complete medium were seeded in 6-well cell culture plates at a cell density of 15 x 10 4 Each well contained 2 mL. After seeding, the 6-well plates were incubated in a cell culture incubator for 24 h.

[0096] (2) Drug administration

[0097] The experiment was divided into the following nine groups: a blank control group, a 0.01% swertia japonica group, a 0.05% swertia japonica group, a 0.1% swertia japonica group, a 0.2% swertia japonica group, a 0.5% swertia japonica group, a 1% swertia japonica group, and a 5% swertia japonica group, with 3 replicate wells in each group. The blank control group was added with an equal volume of PBS. After drug administration, the 6-well plates were incubated in a cell culture incubator for 24 h.

[0098] (3) Extraction of RNA and synthesis of cDNA

[0099] RNA was extracted using a TaKaRa MiniBEST Universal RNA Extraction Kit, and the extracted RNA was then synthesized into cDNA using a PrimeScript TM RT reagent Kit with gDNA Eraser kit, with the specific operation being performed in accordance with the kit instructions.

[0100] (4) Detection of UGT1A1 gene expression level

[0101] The expression level of the UGT1A1 gene was detected using a TB Premix Ex Taq TM kit, with GAPDH serving as an internal reference gene. The reaction system for fluorescence quantitative PCR was set to 10 μL, and the specific sample addition was performed in accordance with the kit instructions. After sample addition, the gene expression level was detected on a real-time fluorescence quantitative PCR system, with the reaction program being as follows: 95°C, 30 s, 40 cycles (95°C, 5 s, 54°C, 30 s).

[0102] (5) Results statistics and analysis

[0103] The relative expression level of the gene was calculated using a 2-ΔΔCt method. GraphPad Prism software was used for plotting, with the gene expression level being expressed as Mean ± SD. The significant difference between two groups of data was analyzed using an independent sample T test.

[0104] (6) Experimental results

[0105] The experimental results of the determination of the expression level of UGT1A1 gene related to bilirubin metabolism are shown in Table 2. Figure 3 Figure 3 It can be seen that, in the concentration range of 0.01% to 0.2%, the expression level of UGT1A1 gene of HaCaT cells gradually increases with the increase of the concentration of Swertia mileensis extract; in the concentration range of 0.2% to 5%, the expression level of UGT1A1 gene of HaCaT cells gradually decreases with the increase of the concentration of Swertia mileensis extract. Specifically, the promotion rates of UGT1A1 gene expression of Swertia mileensis extract at the concentrations of 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1% and 5% are 24.3%, 37.0%, 72.7%, 133.3%, 100.7%, 97.3% and 92.0% respectively, indicating that Swertia mileensis extract may promote bilirubin metabolism to achieve the effect of instant jaundice removal.

[0106] Example 5

[0107] Clinical efficacy test

[0108] (1) Test sample

[0109] Test group: 0.2% Swertia mileensis extract (prepared with base), that is, 0.2% Swertia mileensis extract provided in Example 1 is added to the base.

[0110] Blank control group: base.

[0111] The ingredients and corresponding contents of the base are shown in Table 1.

[0112] Table 1: Ingredient and content table of base

[0113] Ingredient Name Amount Water 90.32％ 1,3-Propanediol 6％ Dimethicone 2％ Pentaerythrityl Tetraethylhexanoate 0.5％ Polyacryloyldimethyl Taurate 0.4％ p-Hydroxyacetophenone 0.4％ 1,2-Hexanediol 0.12％ Gellan Gum 0.08％ Phenoxyethanol 0.06％ Octoxyglycerin 0.06％ Monosodium Phosphate 0.04％ Disodium Phosphate 0.02％ Total 100％

[0114] (2) Test instrument

[0115] Colorimeter (Colorimeter CL400, CK, Germany), transcutaneous jaundice instrument.

[0116] (3) Volunteers

[0117] A total of 35 volunteers participated in this project, and 31 effective volunteers were aged from 22 to 43 years old, with an average age of 29.13 years old, and all were Asian skin.

[0118] (4) Test environment

[0119] Test environment: temperature (21±1) ℃, humidity (50±10)%, and real-time dynamic monitoring was performed.

[0120] (5) Test time

[0121] ​Before use (D0), 15 min after use, next morning after use, 7 days after use (D7).

[0122] (6) Test procedure

[0123] ① Before use (D0)

[0124] After the volunteers arrived, they first cleaned their faces with cleansing products, then sat in the test environment for 30 min, during which they did not drink hot water and beverages. After 30 min, the volunteers received skin color tests and transcutaneous jaundice instrument tests on specific areas of the face.

[0125] ② 15 min after use

[0126] At the first visit, 15 min after the volunteers used the products, they received skin color tests and transcutaneous jaundice instrument tests on specific areas of the face.

[0127] ③ Next morning after use (within 24 hours)

[0128] The volunteers visited next morning after using the products, and sat in the test environment for 30 min, during which they did not drink hot water and beverages. After 30 min, the volunteers received skin color tests and transcutaneous jaundice instrument tests on specific areas of the face.

[0129] ④ 7 days after use (D7)

[0130] The volunteers visited after using the products for 7 consecutive days, and first cleaned their faces with cleansing products, then sat in the test environment for 30 min, during which they did not drink hot water and beverages. After 30 min, the volunteers received skin color tests and transcutaneous jaundice instrument tests on specific areas of the face.

[0131] (7) Data analysis

[0132] The calculation formula of the change rate is: change rate = (measurement value after use - measurement value before use) / measurement value before use x 100%.

[0133] The paired T test method was used to analyze the significant differences between the sample treatment group and the control group, and P<0.05 was considered to have statistical significance, *P<0.05, **P<0.01.

[0134] (8) Experimental results

[0135] ① Skin bilirubin content

[0136] The raw data of the determination of skin bilirubin content are shown in Tables 2 and 3. The results of skin bilirubin content are shown in Table 4, and the change rates are shown in Table 5. Figure 4 Figure 4 ​It can be seen that compared with before use, the skin bilirubin content after using 0.2% swertia japonica extract for 15 min, the next morning and 7 days was significantly reduced, and the reduction rates were 9.73%, 8.37% and 11.54% respectively; while the control group had no significant change in bilirubin content at the three test time points. The above results show that swertia japonica extract can instantly reduce the content of skin bilirubin to achieve the effect of instant yellow removal.

[0137] Table 2 Skin bilirubin content after using 0.2% swertia japonica extract

[0138]

[0139] Table 3 Skin bilirubin content after using base material

[0140]

[0141] ②, skin color data

[0142] The skin color data is shown in Tables 4 to 11. The skin color results are shown in Figures 5 to 8 It can be seen that compared with before use, the skin brightness (L* value) had no significant change after using 0.2% swertia japonica extract for 15 min; the skin brightness was significantly improved after use for the next morning and 7 days, and the improvement rates were 1.66% and 1.23% respectively. From Figure 5 It can be seen that compared with before use, the skin redness (a* value) was significantly reduced after using 0.2% swertia japonica extract for 15 min, the next morning and 7 days, and the reduction rates were 2.71%, 4.31% and 4.19% respectively. From Figure 6 It can be seen that compared with before use, the skin yellow (b* value) was significantly reduced after using 0.2% swertia japonica extract for 15 min, the next morning and 7 days, and the reduction rates were 2.90%, 2.84% and 3.81% respectively. From Figure 7 It can be seen that compared with before use, the skin ITA° value was significantly reduced after using 0.2% swertia japonica extract for the next morning and 7 days, and the reduction rates were 1.81% and 1.61% respectively. Figure 8 The above results show that swertia japonica extract has the clinical effects of instant soothing and instant yellow removal, and also has the early (next morning to 7 days) clinical effects of brightening, soothing, yellow removal and whitening.

[0143] Table 4 Skin brightness (L* value) after using 0.2% swertia japonica extract

[0144]

[0145]

[0146] ​

[0147] Table 5 Skin lightness (L* value) after use of base

[0148]

[0149]

[0150] Table 6 Skin redness (a* value) after use of 0.2% swertia japonica extract

[0151]

[0152] Table 7 Skin redness (a* value) after use of base

[0153]

[0154]

[0155] Table 8 Skin yellowness (b* value) after use of 0.2% swertia japonica extract

[0156]

[0157]

[0158] Table 9 Skin yellowness (b* value) after use of base

[0159]

[0160]

[0161] Table 10 Skin ITA° value after use of 0.2% swertia japonica extract

[0162]

[0163]

[0164] Table 11 Skin ITA° value after use of base

[0165]

[0166]

[0167] Example 6

[0168] Formulation stability test

[0169] Formulate 200 g base (Table 1) and divide into 4 equal parts, add extract of swertia japonica hoo to three parts of the base respectively, so that the final concentration is 0.01wt%, 0.2wt% and 5wt% respectively, and the other part is not treated as a blank control group. Then, place the four groups of samples in a constant temperature incubator at 60 DEG C, and record the appearance and odor of the two groups of samples on the 0th, 3rd, 7th, 15th and 30th day, and measure the pH value of the samples.

[0170] The stability results are shown in Table 12, and it can be seen from Table 12 that: within 30 days, the appearance, odor and pH of the 0.01wt%, 0.2wt% and 5wt% swertia japonica hoo extract groups have no obvious changes, indicating that the swertia japonica hoo extract has high stability in the formula.

[0171] Table 12: Swertia japonica hoo extract stability test record table

[0172]

[0173]

[0174] In summary, the present application first proposes the application of swertia japonica hoo extract in whitening and / or yellow removal, for example, the swertia japonica hoo extract can effectively inhibit the melanin production of B16-F10 cells, thereby achieving the whitening effect; in addition, the swertia japonica hoo extract can promote the expression of UGT1A1 gene related to bilirubin metabolism of HaCaT cells, thereby playing a role in yellow removal by promoting bilirubin metabolism. And the swertia japonica hoo extract can also reduce the content of skin bilirubin, reduce the redness a* value and yellowness b* value of the skin, and improve the brightness L* value of the skin, thereby playing a role in yellow removal. In other words, the swertia japonica hoo extract can effectively solve the problems of skin pigmentation, dullness and yellowing in the safe dosage range, and has great application prospect in the preparation of daily chemical products and / or drugs with whitening and / or yellow removal effect.

[0175] The above only describes the preferred embodiments of the present application and is not intended to limit the present application. For those skilled in the art, the present application can have various modifications and changes. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. The application of a Chinese gentian extract as the sole active ingredient in the preparation of whitening and / or yellowing-reducing products; The extract of *Gynostemma pentaphyllum* was obtained by immersion in an ethanol-water solution with an ethanol concentration of 65% to 75%.

2. The application according to claim 1, characterized in that, The extract of *Gynostemma pentaphyllum* is used to inhibit melanin production; and / or, the extract of *Gynostemma pentaphyllum* is used to increase the expression of the UGT1A1 gene.

3. The application according to claim 1, characterized in that, The extract of *Gynostemma pentaphyllum* is used to reduce bilirubin levels in the skin.

4. The application according to claim 1, characterized in that, The extract of *Gentiana scabra* is used to reduce the yellowness (b* value) of the skin.

5. The application according to claim 1, characterized in that, The extract of *Gentiana scabra* is used to reduce the redness a* value of the skin.

6. The application according to claim 1, characterized in that, The extract of *Gynostemma pentaphyllum* is used to improve the skin's luminance (L* value).

7. The application according to claim 1, characterized in that, The extract of *Gynostemma pentaphyllum* is used to increase the ITA° value of human skin.

8. The application according to any one of claims 1 to 7, characterized in that, The effective concentration of the extract of *Gynostemma pentaphyllum* is 0.01 wt% to 5 wt%.

9. The application according to claim 8, characterized in that, The effective concentration of the extract of *Gynostemma pentaphyllum* is 0.01wt%~0.2wt%.

10. The application according to any one of claims 1 to 7, characterized in that, The preparation of the extract of *Gynostemma pentaphyllum* includes: extracting the pulverized leaves of *Gynostemma pentaphyllum* with an ethanol-water solution of 65% to 75% concentration; the ratio of the ethanol-water solution to the leaves of *Gynostemma pentaphyllum* is 8 mL:1 g to 12 mL:1 g, the extraction temperature is 48℃ to 52℃, and the extraction time is 46 h to 50 h.

Images